BioCentury
ARTICLE | Top Story

MedImmune, GSK antibody deal

August 30, 2005 12:51 AM UTC

GlaxoSmithKline (LSE:GSK; GSK) granted MEDI worldwide rights to anti-staphylococcal monoclonal antibodies (MAbs), including BSYX-A110, which is in Phase IIa testing to prevent serious bloodstream infe...